DK2362915T3 - Crispr-sekvenser fra bifidobakterier - Google Patents

Crispr-sekvenser fra bifidobakterier Download PDF

Info

Publication number
DK2362915T3
DK2362915T3 DK09799777.9T DK09799777T DK2362915T3 DK 2362915 T3 DK2362915 T3 DK 2362915T3 DK 09799777 T DK09799777 T DK 09799777T DK 2362915 T3 DK2362915 T3 DK 2362915T3
Authority
DK
Denmark
Prior art keywords
sequence
seq
crispr
balal
spacer
Prior art date
Application number
DK09799777.9T
Other languages
English (en)
Inventor
Dennis A Romero
Lindsay L Traeger
Rodolph Barrangou
Philippe Horvath
Original Assignee
Dupont Nutrition Biosci Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dupont Nutrition Biosci Aps filed Critical Dupont Nutrition Biosci Aps
Application granted granted Critical
Publication of DK2362915T3 publication Critical patent/DK2362915T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (11)

1. Isoleret nukleinsyre, der omfatter en sekvens af et CRISPR-locus fra bifidobakterier udvalgt fra gruppen, der består af a) Balal (SEQ ID NO: 1); b) en Balal- gentagelsessekvens udvalgt blandt SEQ ID NO: 2 og sekvensvarianter deraf; c) en Balal spacersekvens udvalgt blandt SEQ ID NO: 3-24; hvor sekvensvarianterne af SEQ ID NO: 2 omfatter en eller flere substitutioner udvalgt fra gruppen, der består af: anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
2. Isoleret nukleinsyre ifølge krav 1, hvor sekvensvarianterne af SEQ ID NO: 2 har anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
3. Isoleret nukleinsyre ifølge krav 1, hvor sekvensen er udvalgt blandt SEQ ID NO: 13, 14 og 15.
4. Isoleret nukleinsyre, der omfatter en Balal-gentagelsessekvens af SEQ ID NO: 2 og en Balal-spacersekvens udvalgt blandt SEQ ID NO: 3-24.
5. Vektor, der omfatter et CRISPR-locus udvalgt fra gruppen, der består af a) Balal (SEQ ID NO: 1); b) en Balal- gentagelsessekvens udvalgt blandt SEQ ID NO: 2 og sekvensvarianter deraf; og c) en Balal-spacersekvens udvalgt blandt SEQ ID NO: 3-24; hvor sekvensvarianterne af SEQ ID NO: 2 omfatter en eller flere substitutioner udvalgt fra gruppen, der består af: anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
6. Vektor, der omfatter en Balal-gentagelse-spacer- enhedssekvens, hvor gentagelsessekvensen er udvalgt blandt SEQ ID NO: 2 og varianter deraf, og spacersekvensen er udvalgt blandt SEQ ID NO: 3-24, hvor sekvensvarianterne af SEQ ID NO: 2 omfatter en eller flere substitutioner udvalgt fra gruppen, der består af: anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
7. Rekombinant stamme af bakterier med ændret fagresistens, der omfatter a) en Balal-gentagelsessekvens udvalgt blandt SEQ ID NO: 2 og varianter deraf; og b) en Balal-spacersekvens udvalgt blandt SEQ ID NO: 3-24; hvor sekvensvarianterne af SEQ ID NO: 2 omfatter en eller flere substitutioner udvalgt fra gruppen, der består af: anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
8. Rekombinant stamme af bakterier med ændret fagresistens, der omfatter en Balal-gentagelse-spacer-enhedssekvens, hvor gentagelsessekvensen er udvalgt blandt SEQ ID NO: 2 og varianter deraf, og spacersekvensen er udvalgt blandt SEQ ID NO: 3-24, hvor sekvensvarianterne af SEQ ID NO: 2 omfatter en eller flere substitutioner udvalgt fra gruppen, der består af: anvendelse af C i stedet for T i position 12, anvendelse af C i stedet for T i position 14 og anvendelse af G i stedet for A i position 36.
9. Fremgangsmåde til fremstilling af en rekombinant bakteriestamme med ændret fagresistens, der omfatter: (a) transformering af bakterier med en nukleinsyre, der omfatter en Balal-spacersekvens udvalgt blandt SEQ ID NO: 3-24; (b) etablering af kontakt mellem de transformerede bakterier og en fag; og (c) isolering af transformerede bakterier, der fremviser ændret resistens over for fagen.
10. Fremgangsmåde til stammetypebestemmelse, der omfatter: (a) amplificering af genomisk DNA fra en stamme af interesse ved anvendelse af mindst ét primerpar, hvor det genomiske DNA omfatter mindst en del af en sekvens af et CRISPR-locus, hvor CRISPR-locuset er Balal (SEQ ID NO: 1); (b) påvisning af et amplikon dannet i trin (a) , hvor det påviste amplikon indikerer stammetypen.
11. Stammetypebestemmelseskit, der omfatter: (a) en beholder med en amplifikationsblanding, der omfatter en DNA-polymerase, en amplifikationsbuffer og mindst ét primerpar, hvor hver primer af parret er komplementær til en del af genomisk DNA, således at primerparret amplificerer mindst en del af en gentagelses- eller spacersekvens af et CRISPR-locus Balal (SEQ ID NO: 1); og (b) en beholder med en påvisningsblanding, der omfatter en probe, der er i stand til under stringente betingelser at hybridisere til mindst en del af CRISPR-locuset, der amplificeres ved hjælp af primerparret.
DK09799777.9T 2008-11-07 2009-11-06 Crispr-sekvenser fra bifidobakterier DK2362915T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11267308P 2008-11-07 2008-11-07
PCT/US2009/063497 WO2010054154A2 (en) 2008-11-07 2009-11-06 Bifidobacteria crispr sequences

Publications (1)

Publication Number Publication Date
DK2362915T3 true DK2362915T3 (da) 2017-03-27

Family

ID=42025708

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09799777.9T DK2362915T3 (da) 2008-11-07 2009-11-06 Crispr-sekvenser fra bifidobakterier

Country Status (6)

Country Link
US (1) US10662227B2 (da)
EP (1) EP2362915B1 (da)
DK (1) DK2362915T3 (da)
MX (1) MX337838B (da)
RU (1) RU2570562C2 (da)
WO (1) WO2010054154A2 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066233B2 (en) 2005-08-26 2018-09-04 Dupont Nutrition Biosciences Aps Method of modulating cell resistance
BR112012028805A2 (pt) 2010-05-10 2019-09-24 The Regents Of The Univ Of California E Nereus Pharmaceuticals Inc composições de endorribonuclease e métodos de uso das mesmas.
DK2630156T3 (da) 2010-10-20 2018-12-17 Dupont Nutrition Biosci Aps Crispr-cas sekvenser af lactococcus
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
DK2800811T3 (da) 2012-05-25 2017-07-17 Univ Vienna Fremgangsmåder og sammensætninger til rna-rettet target-dna-modificering og til rna-rettet modulering af transkription
KR102243092B1 (ko) 2012-12-06 2021-04-22 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
IL289396B2 (en) 2013-03-15 2023-12-01 The General Hospital Coporation Using tru-grnas to increase the specificity of RNA-guided genome editing
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US9902973B2 (en) 2013-04-11 2018-02-27 Caribou Biosciences, Inc. Methods of modifying a target nucleic acid with an argonaute
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
EP3019595A4 (en) 2013-07-09 2016-11-30 THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
DE202014010413U1 (de) 2013-09-18 2015-12-08 Kymab Limited Zellen und Organismen
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
CA2944978C (en) * 2014-04-08 2024-02-13 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
EP4039816A1 (en) 2015-05-29 2022-08-10 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
JP7051438B2 (ja) 2015-06-15 2022-04-11 ノース カロライナ ステート ユニバーシティ 核酸およびrnaに基づく抗菌剤の効率的な送達のための方法および組成物
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CA2996888A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Engineered crispr-cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3356533A1 (en) 2015-09-28 2018-08-08 North Carolina State University Methods and compositions for sequence specific antimicrobials
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and their uses
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
SG11201806134SA (en) 2016-01-27 2018-08-30 Oncorus Inc Oncolytic viral vectors and uses thereof
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nuclear base editors and their uses
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
JP7191388B2 (ja) 2017-03-23 2022-12-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸によってプログラム可能なdna結合蛋白質を含む核酸塩基編集因子
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
AU2018273968A1 (en) 2017-05-25 2019-11-28 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
EP3861120A4 (en) 2018-10-01 2023-08-16 North Carolina State University RECOMBINANT TYPE I CRISPR-CAS SYSTEM
EP3921417A4 (en) 2019-02-04 2022-11-09 The General Hospital Corporation ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
WO2020191243A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
DE112021002672T5 (de) 2020-05-08 2023-04-13 President And Fellows Of Harvard College Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
EP0769068B1 (en) * 1994-06-24 2005-10-12 Innogenetics N.V. Simultaneous detection, identification and differentiation of eubacterial taxa using a hybridization assay
US7919277B2 (en) * 2004-04-28 2011-04-05 Danisco A/S Detection and typing of bacterial strains
KR100625090B1 (ko) 2005-03-02 2006-09-20 모딘코리아 유한회사 고 마그네슘 알루미늄 합금용 접합시트 및 고 마그네슘 알루미늄 합금 접합방법
US10066233B2 (en) 2005-08-26 2018-09-04 Dupont Nutrition Biosciences Aps Method of modulating cell resistance
ES2590925T3 (es) 2006-05-19 2016-11-24 Dupont Nutrition Biosciences Aps Microorganismos marcados y métodos de marcado

Also Published As

Publication number Publication date
US20110300538A1 (en) 2011-12-08
EP2362915B1 (en) 2016-12-21
WO2010054154A3 (en) 2010-09-16
MX2011004854A (es) 2011-10-28
MX337838B (es) 2016-03-22
US10662227B2 (en) 2020-05-26
RU2570562C2 (ru) 2015-12-10
RU2011122776A (ru) 2012-12-20
EP2362915A2 (en) 2011-09-07
WO2010054154A2 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
DK2362915T3 (da) Crispr-sekvenser fra bifidobakterier
EP2630156B1 (en) Lactococcus crispr-cas sequences
Ventura et al. Characterization of the groEL and groES loci in Bifidobacterium breve UCC 2003: genetic, transcriptional, and phylogenetic analyses
Jarvik et al. Short-term signatures of evolutionary change in the Salmonella enterica serovar typhimurium 14028 genome
Dutta et al. Horizontal gene transfer and bacterial diversity
Tynkkynen et al. Comparison of ribotyping, randomly amplified polymorphic DNA analysis, and pulsed-field gel electrophoresis in typing of Lactobacillus rhamnosus and L. casei strains
Rodríguez-Nava et al. Use of PCR-restriction enzyme pattern analysis and sequencing database for hsp65 gene-based identification of Nocardia species
Bolotin et al. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
Kelleher et al. Next-generation sequencing as an approach to dairy starter selection
Triplett et al. Genomic analysis of Xanthomonas oryzae isolates from rice grown in the United States reveals substantial divergence from known X. oryzae pathovars
Berglund et al. Run-off replication of host-adaptability genes is associated with gene transfer agents in the genome of mouse-infecting Bartonella grahamii
Szczepanek et al. Comparative genomic analyses of attenuated strains of Mycoplasma gallisepticum
JP2019535324A (ja) CRISPR−Cas9の阻害因子
Schumann et al. The discriminatory power of ribotyping as automatable technique for differentiation of bacteria
Hot et al. Characterization of sal (A), a novel gene responsible for lincosamide and streptogramin A resistance in Staphylococcus sciuri
Miller et al. Large linear plasmids of Borrelia species that cause relapsing fever
Clementino et al. PCR analyses of tRNA intergenic spacer, 16S-23S internal transcribed spacer, and randomly amplified polymorphic DNA reveal inter-and intraspecific relationships of Enterobacter cloacae strains
Xiao et al. Characterization of CRISPR‐Cas systems in Leptospira reveals potential application of CRISPR in genotyping of Leptospira interrogans
CA3031571A1 (en) Highly polymorphic and modular extragenic (h.p.m.e.) markers within specific taxa of microorganisms and use thereof for their differentiation, identification and quantification
Koylass et al. Comparative performance of SNP typing and ‘Bruce-ladder’in the discrimination of Brucella suis and Brucella canis
Tourasse et al. Unusual group II introns in bacteria of the Bacillus cereus group
Picardeau et al. Mycobacterial linear plasmids have an invertron-like structure related to other linear replicons in actinomycetes
Trotter et al. Genome analysis of the obligately lytic bacteriophage 4268 of Lactococcus lactis provides insight into its adaptable nature
Greve et al. Novel RepA‐MCM proteins encoded in plasmids pTAU4, pORA1 and pTIK4 from Sulfolobus neozealandicus
Gillis et al. PCR-based discrimination of emerging Streptococcus pneumoniae serotypes 22F and 33F